This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Opinion: Discussing the phase 3 APPLAUSE-IgAN study results on Fabhalta (iptacopan) in patients with IgA Nephropathy
Ticker(s): NVSWho's the expert?
- Clinical associate professor of Medicine, Nephrology Division
- Treats 25 patients with IgAN
- Familiar with the data released from the phase 2b ORIGIN clinical trial and the phase 3 ALIGN study
Interview GoalTo discuss the current standard of care and the potential of Fabhalta (iptacopan) a Factor B inhibitor being developed by Novartis for the treatment of IgA Nephropathy.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
